Estimates Revisions Tenax Therapeutics, Inc.
Stocks
TENX
US88032L6056
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
Pre-market 11:40:50 | |||
| 1.375 USD | -89.77% |
|
1.450 | +5.45% |
| 08-10 | Tenax Therapeutics Announces Topline Results from Phase 3 Level Clinical Trial of Tnx-103 in Patients with Ph-Hfpef | CI |
| 08-10 | Tenax Therapeutics, Inc. - Special Call |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | - | - | ||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- TENX Stock
- Consensus Tenax Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
